Accredited Co-developed Symposia

Optional Accredited Symposia

You are cordially invited to attend the following additional accredited sessions that have been developed by the CTS to achieve scientific integrity, objectivity and balance.

Space at each session is limited, so plan to arrive early. Access will be based on a first-come, first-served basis. Breakfast will be provided.

Friday, April 28, 2017 – 0715-0815

Precision Medicine in Asthma and the Evolving Role of Biologics
Verdun/Lachine

Speaker:  Dr. Mark FitzGerald, University of British Columbia, Vancouver, BC

This session was developed by the Canadian Thoracic Society with an Independent Medical Education Grant from GlaxoSmithKline Inc.

The significant burden of disease related to hospitalization due to severe asthma is well documented.  The introduction of new biologics presents new options for therapy to improve patient outcomes.  This session will discuss how to assess patients to determine best therapy to treat and prevent severe uncontrolled asthma.

Learning Objectives

At the end of this presentation, attendees will be able to:

  • Appreciate the significant socio-economic burden associated with severe uncontrolled asthma;
  • Recognize our greater understanding of the underlying biology of severe asthma;
  • Provide a framework for assessing a patient who might be candidate for a biologic; and
  • Consider a future framework for the management of asthma and the integration of biologics at an earlier stage.

Saturday, April 29, 2017 – 0715-0815

The Impact of Symptoms and Physical Inactivity on COPD
Verdun/Lachine

Speaker:  Dr. Marc Miravitlles, Hospital Universitari Vall d'Hebron, Barcelona

This session was co-developed by the Canadian Thoracic Society and AstraZeneca Canada.

Patients with COPD present with respiratory symptoms. Dyspnea is the most common cause of respiratory limitation of activity in patients with pulmonary disease. Both increased dyspnea and reduced activity are markers of poor prognosis and therefore strategies to reduce dyspnea must be effective in improve prognosis of the diseases. However, the reduction in dyspnea is not always followed by an increase in activity, and specific strategies must be implemented to increase the level of physical activity in COPD.

The combination of pharmacologic and non-pharmacologic treatments will provide the best approach to reduce symptoms and improve physical activity and quality of life in COPD.

Learning Objectives

At the end of this presentation, attendees will be able to:

  • Understand the prevalence and prognostic value of symptoms in COPD;
  • Evaluate the relationship between dyspnea and inactivity;
  • Understand the prognostic value of physical inactivity;
  • Discuss strategies to improve physical activity; and
  • Discuss pharmacological strategies to improve symptoms and activity.